# US 2024/0197628 A1 · Inhalable dry powder formulations comprising angiogenesis inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197628 A1
- Document ID: US20240197628A1
- Status: Published application
- Kind: A1
- Application number: 18/589,995
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2020-11-18
- Assignees: Lonza Bend Inc.
- Applicants: Lonza Bend Inc.
- Inventors: Kimberly Shepard; Michael Banks; David Vodak
- Web page: https://patentgrep.com/patent/US20240197628A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1682: {Processes}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/245: {IL-1}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to inhalable dry powder formulations comprising one or more antibodies or one or more angiogenesis inhibiting active pharmaceutical ingredients, methods of manufacture of such compositions, e.g., via spray drying, as well as their local administration to the lung for use in the treatment, prevention and/or delay of progression of asthma, COPD, lung infections, cystic fibrosis, or lung cancer.

## Claims

### Claim 1

A dry powder formulation suitable for administration via inhalation comprising one or more antibodies or one or more angiogenesis inhibitors, a small molecular API, a stabilizer, and a dispersant.

### Claim 2 (depends on 1)

The formulation according to claim 1, wherein the angiogenesis inhibitor is a VEGF inhibitor.

### Claim 3 (depends on 1)

The formulation according to claim 1, wherein the angiogenesis inhibitor is:
(a) aflibercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ponatinib, ramucirumab, ranibizumab, regorafenib, sorafenib, sunitinib, vandetanib, or any combination thereof; or
(ii) an antibody selected from bevacizumab, ramucirumab, and ranibizumab.

### Claim 4 (depends on 1)

The formulation according to claim 1, wherein the antibody is benralizumab, dupilumab, lebrikizumab, mepolizumab, omalizumab, reslizumab, tralokinumab, oblitoxaximab, palivizumab, panobacumab, raxibacumab, atezolizumab, avelumab, balstilimab, bevacizumab, camrelizumab, cemiplimab, cetuximab, dostarlimab, durvalumab, necitumumab, nimotuzumab, nivolumab, panitumumab, pembrolizumab, prolgolimab, racotumomab, ramucirumab, ranibizumab, retifanlimab, sintilimab, tislelizumab, toripalimab, or any combination thereof.

### Claim 5 (depends on 1)

The formulation according to claim 1, wherein the small molecular API is selected from cisplatin, carboplatin, topotecan, paclitaxel, erlotinib, or any combination thereof.

### Claim 6 (depends on 1)

The formulation according to claim 1, wherein the stabilizer is selected from trehalose, mannitol, raffinose, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, inulin, pullulan and mixtures thereof.

### Claim 7 (depends on 1)

The formulation according to claim 1, wherein the formulation comprises a dispersant selected from L-leucine, tri-leucine, L-isoleucine, arginine, histidine, glycine, and mixtures thereof.

### Claim 8 (depends on 1)

The formulation according to claim 1, wherein the formulation further comprises a buffer selected from phosphate, tris(hydroxymethyl)aminomethane (TRIS), acetate, glycine, citric acid, carbonate, and mixtures thereof.

### Claim 9 (depends on 1)

The formulation according to claim 1, wherein the formulation comprises:
1 to 90 wt % of the antibody or angiogenesis inhibitor;
1 wt % to 80 wt % of the small molecular API;
10 wt % to 90 wt % of the stabilizer;
2 wt % to 40 wt % of the dispersant;
and less than 5 wt % of buffer;
wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

### Claim 10 (depends on 1)

The formulation according to claim 1, wherein the formulation comprises 1 wt % to 50 wt % of angiogenesis inhibitor, 1 wt % to 50 wt % of small molecular API, 10 wt % to 88 wt % of stabilizer, 5 wt % to 30 wt % of dispersant, and optionally up to 5 wt % buffer, wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

### Claim 11 (depends on 1)

The formulation according to claim 1, wherein the formulation comprises 5 wt % to 40 wt % of bevacizumab, 20 wt % to 80 wt % of trehalose, 10 wt % to 25 wt % of L-leucine, and 5 wt % to 40 wt % of a small molecular API selected from cisplatin, carboplatin, topotecan, paclitaxel, and erlotinib, wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

### Claim 12 (depends on 1)

The formulation according to claim 1, wherein the formulation is a spray dried solid dispersion.

### Claim 13 (depends on 1)

The formulation according to claim 1, wherein the formulation is a spray dried solid dispersion with a particle size distribution of:
d
⁢
90
<
50
⁢
µm
;
(
i
)
d
⁢
50
<
5
⁢
µm
;
or
(
ii
)
d
⁢
90
<
10
⁢
µm
,
d
⁢
50
<
3
⁢
µm
,
and
⁢
d
⁢
10
>
500
⁢
nm
.
(
iii
)

### Claim 14 (depends on 1)

A spray drying process suitable to manufacture a formulation according to claim 1, wherein the process comprises the following steps:
a) preparing a spray drying solution by dissolution of the angiogenesis inhibitor, the small molecular API, the stabilizer, the dispersant and optionally further ingredients in a spray drying solvent;
b) directing a drying gas at a particular inlet temperature at a particular drying gas flow rate into a drying chamber;
c) directing the spray drying solution at a particular liquid flow rate through an atomizing nozzle into the drying chamber, said drying gas exiting the drying chamber at an outlet temperature; and
d) collecting the obtained particles.

### Claim 15 (depends on 1)

A spray drying process suitable to manufacture a formulation according to claim 1, wherein the process comprises the following steps:
a1) preparing a first spray drying solution by dissolution of the small molecular API, optionally the stabilizer, optionally the dispersant and optionally further ingredients in a spray drying solvent;
a2) preparing a second spray drying solution by dissolution of the angiogenesis inhibitor, the stabilizer, the dispersant and optionally further ingredients in a spray drying solvent;
b) directing a drying gas at a particular inlet temperature at a particular drying gas flow rate into a drying chamber;
c1) directing the two spray drying solutions simultaneously at particular liquid flow rates through two separate two-fluid atomizing nozzles into the drying chamber, said drying gas exiting the drying chamber at an outlet temperature;
d) collecting the obtained particles.

### Claim 16 (depends on 1)

A capsule comprising a formulation according to claim 1.

### Claim 17 (depends on 16)

A kit comprising a dry powder inhaler and one or more capsules according to claim 16.

### Claim 18 (depends on 1)

A blister pack or blister strip comprising a formulation according to claim 1.

### Claim 19 (depends on 1)

A method of treatment, prevention, delay of progression, and/or maintenance therapy of asthma, COPD, lung infections, cystic fibrosis, or lung cancer, squamous cell carcinoma, epidermoid carcinoma, or large cell carcinoma, which method comprises administering the formulation according to claim 1 to a human being or animal.

### Claim 20 (depends on 19)

The method of treatment according to claim 19, wherein the formulation is administered via inhalation
(i) twice daily, once daily, twice weekly, once weekly, every two weeks or every three weeks; or
(ii) at a daily overall angiogenesis inhibitor dose of 0.1 mg to 50 mg; or
(iii) every two weeks at a bi-weekly overall angiogenesis inhibitor dose of 1 mg to 200 mg.
